Bicycle Therapeutics plc (NASDAQ:BCYC) Expected to Announce Earnings of -$0.64 Per Share

Equities analysts predict that Bicycle Therapeutics plc (NASDAQ:BCYC) will report ($0.64) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Bicycle Therapeutics’ earnings. The lowest EPS estimate is ($0.76) and the highest is ($0.55). Bicycle Therapeutics posted earnings of ($0.52) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 23.1%. The firm is expected to report its next earnings report on Thursday, November 4th.

According to Zacks, analysts expect that Bicycle Therapeutics will report full-year earnings of ($2.76) per share for the current year, with EPS estimates ranging from ($3.36) to ($2.02). For the next year, analysts forecast that the company will post earnings of ($2.81) per share, with EPS estimates ranging from ($4.61) to ($0.71). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that that provide coverage for Bicycle Therapeutics.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Thursday, August 5th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.03). Bicycle Therapeutics had a negative return on equity of 50.43% and a negative net margin of 546.62%. The company had revenue of $1.79 million for the quarter, compared to the consensus estimate of $2.51 million.

A number of equities research analysts have commented on the stock. Zacks Investment Research lowered shares of Bicycle Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 6th. Piper Sandler increased their price objective on shares of Bicycle Therapeutics from $39.00 to $46.00 and gave the stock an “overweight” rating in a report on Tuesday, July 13th. JMP Securities reissued a “buy” rating and set a $53.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, August 11th. Finally, Canaccord Genuity increased their price objective on shares of Bicycle Therapeutics from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, July 13th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $44.43.

NASDAQ:BCYC traded down $1.08 during mid-day trading on Friday, reaching $41.27. 440 shares of the company were exchanged, compared to its average volume of 149,546. Bicycle Therapeutics has a 12 month low of $17.68 and a 12 month high of $45.21. The company has a fifty day moving average of $34.62 and a 200 day moving average of $31.40. The company has a quick ratio of 9.36, a current ratio of 9.36 and a debt-to-equity ratio of 0.21. The stock has a market cap of $1.05 billion, a PE ratio of -15.02 and a beta of -0.34.

In related news, CFO Lee Kalowski sold 12,500 shares of the stock in a transaction that occurred on Thursday, July 29th. The shares were sold at an average price of $31.51, for a total value of $393,875.00. Following the sale, the chief financial officer now directly owns 12,500 shares in the company, valued at approximately $393,875. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin Lee sold 1,936 shares of the stock in a transaction that occurred on Monday, July 12th. The shares were sold at an average price of $32.04, for a total transaction of $62,029.44. The disclosure for this sale can be found here. Insiders sold a total of 136,447 shares of company stock worth $4,536,400 in the last ninety days. Insiders own 17.90% of the company’s stock.

Large investors have recently made changes to their positions in the stock. WealthShield Partners LLC acquired a new stake in shares of Bicycle Therapeutics in the 2nd quarter valued at approximately $27,000. Citigroup Inc. raised its holdings in Bicycle Therapeutics by 107.8% during the 2nd quarter. Citigroup Inc. now owns 1,066 shares of the company’s stock worth $32,000 after buying an additional 553 shares during the period. JPMorgan Chase & Co. acquired a new stake in Bicycle Therapeutics during the 1st quarter worth approximately $39,000. Personal CFO Solutions LLC acquired a new stake in Bicycle Therapeutics during the 2nd quarter worth approximately $221,000. Finally, Geode Capital Management LLC acquired a new stake in Bicycle Therapeutics during the 2nd quarter worth approximately $227,000. Institutional investors and hedge funds own 48.67% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles.

See Also: What are the disadvantages of after-hours trading?

Get a free copy of the Zacks research report on Bicycle Therapeutics (BCYC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.